AN INNOVATIVE PREP RESEARCH STUDY FOR WOMEN
HPTN 084 (LIFE) is a research study that compares the effectiveness of injections and oral tablets as pre-exposure prophylaxis (PrEP) to prevent HIV in women.
-
<h3 class="ht-section-title" style="text-align: center;"><span style="color: #ff69b4;">CABOTEGRAVIR FOR PREP</span></h3> <h6 style="text-align: center;"><span style="color: #000000;">HPTN 084 (LIFE) is the first study to test if an injection of cabotegravir (CAB) given once every two months works better than a Truvada pill taken every day for HIV prevention in women. Truvada consists of the two anti-HIV drugs – emtricitabine and tenofovir disoproxil fumarate (TDF/FTC).</span></h6>
HPTN 084 will enroll participants in 20 sites in 7 countries in sub-Saharan Africa: Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda and Zimbabwe.
See site contact information here.
The HPTN
HPTN 084 is a study that is part of the NIH-DAIDS-funded HIV Prevention Trials Network (HPTN). Learn more under Additional Information.
<!-- Global site tag (gtag.js) - Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=UA-109684911-1"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-109684911-1');
</script>
<!-- Hotjar Tracking Code for https://084life.org/ -->
<script>
(function(h,o,t,j,a,r){
h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
h._hjSettings={hjid:704812,hjsv:6};
a=o.getElementsByTagName('head')[0];
r=o.createElement('script');r.async=1;
r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
a.appendChild(r);
})(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
</script>